Skip to content
Biotron Limited
  • Home
  • About Us
    • Board of Directors
    • Management Team
  • Technology
    • Clinical programs
    • Non-clinical programs
    • Intellectual property
  • News/Resources
    • Newsletters
    • In the news
    • Scientific Presentations
    • Scientific Publications
  • Investor Centre
    • ASX Announcements
    • Financial Reports
      • Annual
      • Half-year
      • Quarterly
    • Corporate Directory
    • Shareholder services
    • Rights Issue
    • Top 40 Shareholders
    • Top 40 Option Holders
    • Corporate Governance
    • Corporate Presentations
  • Contacts

2013

Presentation of HIV Data at International HIV Persistence Meeting

5 December 2013 by Justine Bednorz

Presentation of HIV Data at International HIV Persistence Meeting

Categories 2013, ASX Announcements

Independent Research Validates Biotron HCV Drug Candidate

27 November 2013 by Justine Bednorz

Independent Research Validates Biotron HCV Drug Candidate

Categories 2013, ASX Announcements

Ethics Approval for New HCV Three Month Dosing Study

21 November 2013 by Justine Bednorz

Ethics Approval for New HCV Three Month Dosing Study

Categories 2013, ASX Announcements

Director Change

8 November 2013 by Justine Bednorz

Director Change

Categories 2013, ASX Announcements

Results of Annual General Meeting

8 November 2013 by Justine Bednorz

Results of Annual General Meeting

Categories 2013, ASX Announcements

Presentation to Annual General Meeting

28 February 20148 November 2013 by Justine Bednorz

Presentation to Annual General Meeting

Categories 2013, ASX Announcements

Biotron Details Headline Trial Data at International Liver Conference

6 November 2013 by Justine Bednorz

Biotron Details Headline Trial Data at International Liver Conference

Categories 2013, ASX Announcements

Biotron to Present at Australia Biotech Invest 2013

28 October 2013 by Justine Bednorz

Biotron to Present at Australia Biotech Invest 2013

Categories 2013, ASX Announcements

BIT225 Enhances Anti-viral Activity In HIV/HCV Genotype 3 Co-infected Patients; Phase 2 Data To Be Presented At Leading International Liver Meeting

25 October 2013 by Justine Bednorz

BIT225 Enhances Anti-viral Activity In HIV/HCV Genotype 3 Co-infected Patients; Phase 2 Data To Be Presented At Leading International Liver Meeting

Categories 2013, ASX Announcements

Quarterly Report 30 September 2013

21 October 2013 by Justine Bednorz

Quarterly Report 30 September 2013

Categories 2013, Quarterly Reports
Older posts
Page1 Page2 Page3 Next →
© Biotron Limited 2016       ABN 60 086 399 144        Site updated 25 June 2025        Legal Notices and Privacy
Cleantalk Pixel